BioVie Inc. (BIVI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

BioVie Inc. (BIVI) closed at USD 1.16 on 2026-10-14, a change of -37.6 % over the past year, with a market capitalization of USD 9.81M.

BioVie Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

BioVie Inc. key figures

Previous close

USD 1.16 (2026-10-14)

1-year change

-37.6 %

Market cap

USD 9.81M

Enterprise value

USD -178,759

P/E ratio (trailing)

-0.39

P/E ratio (forward)

-1.98

EPS (trailing)

-2.91

EPS (forward)

-0.57

PEG ratio

n/a

Price to book

0.83

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.95

Employees

13

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About BioVie Inc.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for BioVie Inc. and compare it with other stocks.